JP2020504733A5 - - Google Patents

Download PDF

Info

Publication number
JP2020504733A5
JP2020504733A5 JP2019533490A JP2019533490A JP2020504733A5 JP 2020504733 A5 JP2020504733 A5 JP 2020504733A5 JP 2019533490 A JP2019533490 A JP 2019533490A JP 2019533490 A JP2019533490 A JP 2019533490A JP 2020504733 A5 JP2020504733 A5 JP 2020504733A5
Authority
JP
Japan
Prior art keywords
amino
methyl
oxy
propan
phosphoryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019533490A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504733A (ja
JP6938637B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/067470 external-priority patent/WO2018119013A1/en
Publication of JP2020504733A publication Critical patent/JP2020504733A/ja
Publication of JP2020504733A5 publication Critical patent/JP2020504733A5/ja
Application granted granted Critical
Publication of JP6938637B2 publication Critical patent/JP6938637B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019533490A 2016-12-22 2017-12-20 テノホビルの抗ウイルス性脂肪族エステルプロドラッグ Expired - Fee Related JP6938637B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662437753P 2016-12-22 2016-12-22
US62/437,753 2016-12-22
US201762574493P 2017-10-19 2017-10-19
US62/574,493 2017-10-19
PCT/US2017/067470 WO2018119013A1 (en) 2016-12-22 2017-12-20 Antiviral aliphatic ester prodrugs of tenofovir

Publications (3)

Publication Number Publication Date
JP2020504733A JP2020504733A (ja) 2020-02-13
JP2020504733A5 true JP2020504733A5 (enExample) 2021-01-28
JP6938637B2 JP6938637B2 (ja) 2021-09-22

Family

ID=60972454

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019533490A Expired - Fee Related JP6938637B2 (ja) 2016-12-22 2017-12-20 テノホビルの抗ウイルス性脂肪族エステルプロドラッグ

Country Status (13)

Country Link
US (1) US10519159B2 (enExample)
EP (1) EP3559011B1 (enExample)
JP (1) JP6938637B2 (enExample)
KR (1) KR20190100250A (enExample)
CN (1) CN110099912B (enExample)
AU (1) AU2017379850B2 (enExample)
BR (1) BR112019013017A2 (enExample)
CA (1) CA3047573A1 (enExample)
MA (1) MA47094A (enExample)
MX (1) MX388757B (enExample)
RU (1) RU2759902C2 (enExample)
TW (1) TW201829412A (enExample)
WO (1) WO2018119013A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100108A1 (en) 2015-12-10 2017-06-15 Merck Sharp & Dohme Corp. Antiviral phosphodiamide prodrugs of tenofovir
WO2017106069A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
WO2018039157A1 (en) * 2016-08-25 2018-03-01 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
US10662416B2 (en) 2016-10-14 2020-05-26 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
US10736908B2 (en) 2016-10-26 2020-08-11 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
KR20190100249A (ko) 2016-12-22 2019-08-28 머크 샤프 앤드 돔 코포레이션 항바이러스 벤질-아민 포스포디아미드 화합물
KR102492187B1 (ko) 2017-12-20 2023-01-27 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
EP3730503B1 (en) * 2017-12-21 2026-01-28 Shenzhen TargetRx, Inc. Antiviral nucleoside reverse transcriptase inhibitor
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
CN108586239B (zh) * 2018-04-11 2020-12-29 深圳市前海博扬研究院有限公司 一种3-羟基丙酸甲酯的制备方法
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
US11826375B2 (en) 2018-07-19 2023-11-28 Merck Sharp & Dohme Llc Phosphinic amide prodrugs of tenofovir
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
HRP20240541T1 (hr) 2018-10-31 2024-07-05 Gilead Sciences, Inc. Supstituirani spojevi 6-azabenzimidazola kao inhibitori hpk1
JP7503558B2 (ja) 2019-01-25 2024-06-20 ブラウン ユニバーシティ 加齢関連炎症および障害を治療する、予防するまたは逆転させるための組成物および方法
AU2020231115B2 (en) 2019-03-07 2025-02-20 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
DK3934757T3 (da) 2019-03-07 2023-04-17 Inst Of Organic Chemistry And Biochemistry Ascr V V I 2'3'-cykliske dinukleotider og prodrugs deraf
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
KR102054104B1 (ko) * 2019-04-30 2019-12-09 유니셀랩 주식회사 신규한 테노포비어 알라펜아미드 염 및 이의 제조방법
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
KR102776925B1 (ko) 2019-06-25 2025-03-11 길리애드 사이언시즈, 인코포레이티드 Flt3l-fc 융합 단백질 및 사용 방법
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
FI4037708T3 (fi) 2019-09-30 2024-10-31 Gilead Sciences Inc Hbv-rokotteita ja menetelmiä, hbv:n hoitamiseksi
EP4567109A3 (en) 2019-12-06 2025-09-17 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
CN111018916B (zh) * 2019-12-30 2022-04-29 天津天士力圣特制药有限公司 一种替诺福韦苯基烷基酯膦酰胺前体的合成方法
US11718637B2 (en) 2020-03-20 2023-08-08 Gilead Sciences, Inc. Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same
EP4192474B1 (en) * 2020-08-07 2025-09-10 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
WO2022066882A1 (en) * 2020-09-23 2022-03-31 Oncolinea Pharmaceuticals, Inc. Method for treating cancer with a reverse transcriptase inhibitor
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
TW202310852A (zh) 2021-05-13 2023-03-16 美商基利科學股份有限公司 TLR8調節化合物及抗HBV siRNA療法之組合
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
CN117480155A (zh) 2021-06-23 2024-01-30 吉利德科学公司 二酰基甘油激酶调节化合物
US11999733B2 (en) 2021-06-23 2024-06-04 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240243A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
OA12393A (en) 2000-07-21 2006-04-18 Gilead Sciences Inc Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same.
PL2204374T3 (pl) 2003-12-30 2012-11-30 Gilead Sciences Inc Fosfoniany nukleozydów i ich analogi do leczenia zakażeń HPV
WO2006114064A2 (en) 2005-04-25 2006-11-02 Institute Of Organic Chemistry And Biochemistry Ofthe Academy Of Sciences Of The Czech Republic Use of compounds to enhance processivity of telomerase
WO2007002912A2 (en) 2005-06-29 2007-01-04 Gilead Sciences, Inc. Anti-proliferative compounds, compositions, and methods of use thereof
AU2007269557B2 (en) 2006-07-07 2013-11-07 Gilead Sciences, Inc. Modulators of toll-like receptor 7
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
US9156874B2 (en) * 2011-01-03 2015-10-13 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
CN103403014B (zh) 2011-01-03 2016-07-06 河南美泰宝生物制药有限公司 O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途
CN102887901B (zh) 2011-07-01 2015-01-07 四川好医生攀西药业有限责任公司 无环核苷酸类似物及其制备方法和应用
JP5651275B2 (ja) 2011-08-16 2015-01-07 ギリアード サイエンシス インコーポレーテッド テノホビルアラフェナミドヘミフマレート
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
CN103435672A (zh) * 2013-04-25 2013-12-11 刘沛 含有取代苄基的新型核苷磷酸酯前药的结构与合成
WO2015197006A1 (zh) * 2014-06-25 2015-12-30 四川海思科制药有限公司 一种取代的氨基酸硫酯类化合物、其组合物及应用
CN112898345A (zh) 2014-09-15 2021-06-04 加利福尼亚大学董事会 核苷酸类似物
CN106188139B (zh) * 2015-05-29 2020-02-18 江苏天士力帝益药业有限公司 替诺福韦单苄酯磷酸酰胺前药、其制备方法及应用
WO2017007701A1 (en) 2015-07-07 2017-01-12 Merck Sharp & Dohme Corp. Antiviral phosphodiamide compounds
EP3334743B1 (en) 2015-08-10 2023-11-29 Merck Sharp & Dohme LLC Antiviral beta-amino acid ester phosphodiamide compounds
US10377782B2 (en) 2015-09-15 2019-08-13 The Regents Of The University Of California Nucleotide analogs
CN106167504A (zh) 2015-11-04 2016-11-30 洛阳聚慧医药科技有限公司 非环核苷磷酰胺d‑氨基酸酯衍生物及其盐的制备以及在抗病毒方面的应用
RU2604068C1 (ru) * 2015-12-10 2016-12-10 Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук N-(2-аминопурин-6-ил)глицил-(s)-глутаминовая кислота, обладающая противотуберкулёзной активностью
WO2017100108A1 (en) 2015-12-10 2017-06-15 Merck Sharp & Dohme Corp. Antiviral phosphodiamide prodrugs of tenofovir
WO2017106069A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
WO2018039157A1 (en) * 2016-08-25 2018-03-01 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
US10736908B2 (en) 2016-10-26 2020-08-11 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
KR20190100249A (ko) 2016-12-22 2019-08-28 머크 샤프 앤드 돔 코포레이션 항바이러스 벤질-아민 포스포디아미드 화합물

Similar Documents

Publication Publication Date Title
JP2020504733A5 (enExample)
RU2019122414A (ru) Антивирусные алифатические сложноэфирные пролекарства тенофовира
JP2017105793A5 (enExample)
JP2016179996A5 (enExample)
JP2021063088A5 (enExample)
RU2019122625A (ru) Противовирусные бензиламин-фосфодиамидные соединения
JP2019500387A5 (enExample)
JP2014508804A5 (enExample)
JP2018035142A5 (enExample)
JP2017518334A5 (enExample)
JP2009535352A5 (enExample)
JP2017523225A5 (enExample)
JP2013518107A5 (enExample)
JP2010501584A5 (enExample)
MA46038A (fr) Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale
JP2019501130A5 (enExample)
JP2014505107A5 (enExample)
RU2018127728A (ru) Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич
JP2020512337A5 (enExample)
JP2018529671A5 (enExample)
JP2014500265A5 (enExample)
TN2013000257A1 (en) Immunosuppressant formulations
JP2020128426A5 (enExample)
HRP20201780T1 (hr) Prolijekovi inhibitora hiv reverzne transkriptaze
JP2019531356A5 (enExample)